Individualized growth hormone dosing based on first-year responsiveness in short prepubertal children

Phase 3, randomised, open-label trial of somatropin in growth disorder, growth hormone deficiency (GHD) and Idiopathic Short Stature (ISS) (2 arms), sponsored by University of Gothenburg. Primary endpoints: Height after 3 years of treatment or onset of puberty and Proportion reaching height SDS -0.5 after 3 years. Started May 2007; status: active.